Literature DB >> 23101953

Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump.

Akio Kuroda1, Tetsuyuki Yasuda, Mitsuyoshi Takahara, Fumie Sakamoto, Ryuichi Kasami, Kazuyuki Miyashita, Sumiko Yoshida, Eri Kondo, Ken-ichi Aihara, Itsuro Endo, Taka-aki Matsuoka, Hideaki Kaneto, Toshio Matsumoto, Iichiro Shimomura, Munehide Matsuhisa.   

Abstract

BACKGROUND: To optimize insulin dose using insulin pump, basal and bolus insulin doses are widely calculated from total daily insulin dose (TDD). It is recommended that total daily basal insulin dose (TBD) is 50% of TDD and that the carbohydrate-to-insulin ratio (CIR) equals 500 divided by TDD. We recently reported that basal insulin requirement is approximately 30% of TDD. We therefore investigated CIR after adjustment of the proper basal insulin rate. SUBJECTS AND METHODS: Forty-five Japanese patients with type 1 diabetes were investigated during several weeks of hospitalization. The patients were served standard diabetes meals (25-30 kcal/kg of ideal body weight). Each meal omission was done to confirm basal insulin rate. Target blood glucose level was set at 100 and 150 mg/dL before and 2 h after each meal, respectively. After the basal insulin rate was fixed and target blood glucose levels were achieved, TBD, CIR, TDD, and their products were determined.
RESULTS: Mean (±SD) blood glucose levels before and 2 h after meals were 121±47 and 150±61 mg/dL, respectively. TDD was 31.5±9.0 U, and TBD was 27.0±6.5% of TDD. CIR×TDD of breakfast was significantly lower than those of lunch and supper (288±73 vs. 408±92 and 387±83, respectively; P<0.01).
CONCLUSIONS: CIR has diurnal variance and is estimated from the formula CIR=300/TDD at breakfast or CIR=400/TDD at lunch and supper in type 1 diabetes patients. These results indicate that the insulin dose has been underestimated by using previously established calculations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23101953     DOI: 10.1089/dia.2012.0109

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  6 in total

Review 1.  Reassessment of insulin dosing guidelines in continuous subcutaneous insulin infusion treated type 1 diabetes.

Authors:  Allen Bennett King
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

2.  Carbohydrate-to-Insulin Ratio in a Mediterranean Population of Type 1 Diabetic Patients on Continuous Subcutaneous Insulin Infusion Therapy.

Authors:  Valeria Alcántara-Aragón; Cintia Gonzalez; Rosa Corcoy; Justa Ubeda; Ana Chico
Journal:  J Diabetes Sci Technol       Date:  2014-12-17

3.  Glycemic control status, diabetes management patterns, and clinical characteristics of adults with type 1 diabetes in Japan: Study of Adults' Glycemia in T1DM subanalysis.

Authors:  Norio Abiru; Akira Shimada; Rimei Nishimura; Munehide Matsuhisa; Asuka Ozaki; Hiroshi Ikegami
Journal:  Diabetol Int       Date:  2021-04-25

4.  Diurnal variation of carbohydrate insulin ratio in adult type 1 diabetic patients treated with continuous subcutaneous insulin infusion.

Authors:  Tomoaki Nakamura; Yushi Hirota; Naoko Hashimoto; Tomokazu Matsuda; Michinori Takabe; Kazuhiko Sakaguchi; Wataru Ogawa; Susumu Seino
Journal:  J Diabetes Investig       Date:  2013-09-02       Impact factor: 4.232

Review 5.  A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.

Authors:  Allen B King; Akio Kuroda; Munehide Matsuhisa; Todd Hobbs
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

6.  Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index.

Authors:  Yukari Mitsui; Akio Kuroda; Masashi Ishizu; Hiroyasu Mori; Kiyoe Kurahashi; Takeshi Kondo; Sumiko Yoshida; Yuko Akehi; Ken-Ichi Aihara; Itsuro Endo; Masahiro Abe; Munehide Matsuhisa
Journal:  J Diabetes Investig       Date:  2021-05-03       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.